Home|Journals|Articles by Year Follow on Twitter| Subscribe to List

Directory for Medical Articles

Open Access

Review Article

Prevention and treatment of cyclophosphamide and ifosfamide-induced hemorrhagic cystitis

Ertan Altaylı, Ercan Malkoc, Bilal Fırat Alp, Ahmet Korkmaz.

Warning: mysql_num_rows() expects parameter 1 to be resource, boolean given in /home2/bibliomed/depo/functions_site.php on line 126

Cited by (5)

Free radicals and non-radical reactive molecules as well as several cytokines (e.g. tumor necrosis factor-α and interleukin family) and transcription factors (e.g. nuclear factor-κB and activator protein-1) are now known to take part in the pathogenesis of cyclophosphamide (CP) and ifosfamide (IF) induced hemorrhagic cystitis (HC). When these molecular factors are taken into account pathogenesis of bladder toxicity can be summarized in three steps: (1) acrolein rapidly enters into the uroepithelial cells, (2) activates intracellular ROS and NO production (directly or through transcription factors) leading to peroxynitrite production, and (3) finally the elevated peroxynitrite level basically damages lipids (lipid peroxidation), proteins (protein oxidation) and DNA (strand breaks) leading to PARP activation, a DNA repair enzyme. DNA damage causes PARP overactivation, resulting in the depletion of oxidized nicotinamide adenine dinucleotide (NAD+) and adenosine triphosphate (ATP), and consequently in necrotic cell death.
There is no doubt that for an effective prevention against CP- and IF-cystitis all pathophysiological mechanisms must be taken into consideration. Experimental works reporting beneficial effects of antioxidants, iNOS inhibitors, cytokine blockers or hyperbaric oxygen (HBO) treatment, against CP- and/or IF-induced HC exist in literature. In this article, we discussed the possible mechanisms and effectiveness of agents used in addition to mesna to prevent CP- and IF-cystitis. In conclusion, antioxidants, iNOS inhibitors, peroxynitrite scavengers, anti-inflammatory agents, as well as HBO therapy may be added to mesna administration in clinical trials in order to obtain the best protocol to improve quality of patients comfort.

Key words: cyclophosphamide, ifosfamide, cystitis, mesna, antioxidants, hyperbaric oxygen

Full-text options

Full-text Article

Readers of this article also read the following articles
»The effect of maternal anthropometric characteristics and social factors on birth weight of child in small town hospital of Gandevi block of Navsari district.
»Shifting trends of HIV epidemiology among most at risk groups (MARGs) in India
»Toxicities due to highly active anti-retroviral therapy (HAART) in HIV-positive children: need for further medical research
»Prevalence of overweight and obesity in affluent adolescent girls in Surat city, western India
»Sample size in clinical research, the number we need
»Delayed onset renal failure following multiple bee stings
»Beware – statistics may deceive you
»Why one more journal?
»A study of sacrum with three pairs of sacral foramina in western India
»Need of medicines information OPD in tertiary health care settings: A cross sectional study
»Relationship between serum BDNF levels and cognitive functions, cortisol levels in depressive disorder?

Journal of Environmental and Occupational Science


BiblioMed Home
Follow ScopeMed on Twitter
Author Tools
eJPort Journal Hosting
About BiblioMed
License Information
Terms & Conditions
Privacy Policy
Contact Us

The articles in Bibliomed are open access articles licensed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License (https://creativecommons.org/licenses/by-nc-sa/4.0/) which permits unrestricted, non-commercial use, distribution and reproduction in any medium, provided the work is properly cited.
ScopeMed is a Database Service for Scientific Publications. Copyright © ScopeMed® Information Services.